Feasibility and Tolerability of Anlotinib Plus PD-1 Inhibitors for Previously-Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study
Anlotinib plus PD-1 inhibitors demonstrated a tolerable safety profile and encouraging therapeutic activity as subsequent-line therapy in patients with advanced NSCLC. This conclusion should be confirmed in prospective large-scale clinical trials subsequently.
Authors
- Sa Xiao (ORCID: https://orcid.org/0000-0002-4574-1406)
- Jing Kuang (ORCID: https://orcid.org/0000-0002-2058-7297)
- Shixia Zhou
- Haili Wang (ORCID: https://orcid.org/0000-0002-0310-8143)
- Min Li (ORCID: https://orcid.org/0000-0001-8786-5629)
Institutions
- Second Affiliated Hospital of Zhengzhou University (CN)
- Zhengzhou People's Hospital (CN)
Publication Details
- Journal
- Biologics
- Published
- 2024-11-01
- DOI
- https://doi.org/10.2147/btt.s489363
- Citations
- 5
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.41